AbbVie: Skyrizi Met Endpoints in Phase 3 Plaque Psoriasis Study
January 14 2020 - 9:37AM
Dow Jones News
By Michael Dabaie
AbbVie Inc. (ABBV) said Skyrizi met the primary and all ranked
secondary endpoints, including superiority at week 52, versus
Cosentyx in a head-to-head Phase 3 study in adults with moderate to
severe plaque psoriasis.
Skyrizi showed significantly higher rates of skin clearance
compared with Cosentyx, meeting the primary endpoint of superiority
with at least a 90% improvement from baseline in the Psoriasis Area
and Severity Index at week 52, AbbVie said.
AbbVie shares were up 1% to $87.64 premarket trade Tuesday.
The safety profile of Skyrizi was consistent with that observed
in previously reported studies, with no new safety signals observed
through week 52, the company said.
Skyrizi is part of a collaboration between Boehringer Ingelheim
and AbbVie, with AbbVie leading development and commercialization
globally.
Write to Michael Dabaie at michael.dabaie@wsj.com
(END) Dow Jones Newswires
January 14, 2020 09:22 ET (14:22 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
AbbVie (NYSE:ABBV)
Historical Stock Chart
From Aug 2024 to Sep 2024
AbbVie (NYSE:ABBV)
Historical Stock Chart
From Sep 2023 to Sep 2024